CLOs on the Move

Biostar Ventures

www.biostarventures.com

 
BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.biostarventures.com
  • 560 W Mitchell Street Suite 500
    Petoskey, MI USA 49770
  • Phone: 231 487 9186
  • Fax: 231 487 9183

Executives

Name Title Contact Details

Similar Companies

WHPM Biotech

WHPM Biotech is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Zymo Research Corporation

Zymo Research Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenWay Biotech

GenWay Biotech is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UBC Heart + Lung Institute

UBC Heart + Lung Institute is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.